IPP Bureau
Bayer submits supplemental new drug application to USFDA seeking expanded indication for NUBEQA
By IPP Bureau - September 29, 2024
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Amcor's long-term SBTi targets confirmed
By IPP Bureau - September 28, 2024
The net-zero target approval complements the company's near-term emission reduction targets
Lupin signs distribution agreement with Celnova for orphan drug NaMuscla
By IPP Bureau - September 28, 2024
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
AbbVie submits Biologics license application to USFDA for Telisotuzumab Vedotin
By IPP Bureau - September 28, 2024
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
FDA approves Bristol Myers Squibb’s Cobenfy
By IPP Bureau - September 28, 2024
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Baxter launches nextgen airway clearance system
By IPP Bureau - September 28, 2024
Developed in consultation with clinicians and patients for an enhanced user experience
Zydus receives USFDA final approval for Enzalutamide Capsules, 40 mg
By IPP Bureau - September 28, 2024
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
AIIA starts “Ayurveda innovation for Global Health” campaign
By IPP Bureau - September 28, 2024
Potential of Ayurveda’s contribution in global health system through various innovative practices
India releases revised operational guidelines of non-alcoholic fatty liver disease
By IPP Bureau - September 28, 2024
India has taken the lead in recognising NAFLD as a major non-communicable disease
India reaffirms commitment to social determinants of health at UNGA
By IPP Bureau - September 28, 2024
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Takara Bio Europe unveils new large-scale NGS profiling system and chemistries
By IPP Bureau - September 27, 2024
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
Torrent Pharmaceuticals refutes claims of Shelcal 500 allegedly failing CDSCO quality test
By IPP Bureau - September 27, 2024
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress
By IPP Bureau - September 27, 2024
The company will also share results in two additional posters for deuruxolitinib
Krsnaa Diagnostics acquires stake in Apulki Healthcare
By IPP Bureau - September 27, 2024
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
